Canada markets closed

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1079+0.0152 (+16.40%)
At close: 02:16PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Canadian Patent Grant Strengthens Small Pharma’s International Position

    Further Composition of Matter protection for SPL028, the Company’s next candidate expected to enter the clinicLONDON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as of July 19, 2022 it has been granted patent no. 3104072 by the Canadian Intellectual Property Office. This Canadian patent protects Com

  • GlobeNewswire

    U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

    Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received Issue Notification from the United States Patent and Trademark Office that its patent application no. 17/459,284 will be granted on August 9

  • GlobeNewswire

    George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer

    Building on strong foundations to take Small Pharma through development to commercial success Peter Rands to take on role as Chief Innovation & Intellectual Property Officer LONDON, July 18, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce that the Company’s board of directors (the “Board”) has appointed Mr. Ge